Intercept Pharmaceuticals says they’ve cleared one of the high bars on their Phase III NASH study of obeticholic acid (OCA), setting up a pioneering marketing pitch in the coming months.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,000+ biopharma pros who read Endpoints News by email every day.Free Subscription